<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02141373</url>
  </required_header>
  <id_info>
    <org_study_id>PRT-CTU-0912/03 Version 5.0</org_study_id>
    <nct_id>NCT02141373</nct_id>
  </id_info>
  <brief_title>Effectivenes of Cyanoacrylate (Glubran 2®) in Reducing Seroma Formation in Breast Cancer Patients Post-Axillary Dissection</brief_title>
  <official_title>Effectivenes of Cyanoacrylate (Glubran 2®) in Reducing Seroma Formation in Breast Cancer Patients Post-Axillary Dissection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King Hussein Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King Hussein Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glubran 2 as a surgical glue maybe effective in reducing seroma formation post axillary
      dissection in breast cancer patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total drainage volume</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total seroma aspirate volume</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of fluid drainage</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to drain removal</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of seroma aspirations</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Additional costs incurred due to the need of aspirations</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Glubran 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glubran 2 will be used at end of surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Surgery</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Glubran 2</intervention_name>
    <arm_group_label>Glubran 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The Patient should be above 18 years old

          -  The Patients has Node positive breast cancer

          -  The Patient is eligible for axillary dissection in addition to a surgical intervention
             for the primary tumor

          -  Patients whose sentinel lymph nodes test positive during surgery.

          -  The patient is willing to sign an informed consent to participation

        Exclusion Criteria:

          -  Platelet count is less than 100000

          -  Obese patients with a BMI of more than 35

          -  Patients who need immediate breast reconstruction surgery

          -  Patients who are receiving anticoagulation therapy or have coagulation disorders

          -  Pregnant or lactating patients

          -  Patients who are on steroid therapy

          -  Patients who received chest radiotherapy

          -  Patients who received neoadjuvant chemotherapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahmoud Al Masri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King Hussein Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mahmoud AlMasri, MD</last_name>
    <phone>009625300460</phone>
    <email>Malmasri@KHCC.JO</email>
  </overall_contact>
  <location>
    <facility>
      <name>King Hussein Cancer Center</name>
      <address>
        <city>Amman</city>
        <zip>1269 /11941</zip>
        <country>Jordan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Faiez Daoud, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohammed Hamdan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mahmoud Al-Masri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Jordan</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2014</study_first_submitted>
  <study_first_submitted_qc>May 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2014</study_first_posted>
  <last_update_submitted>April 2, 2015</last_update_submitted>
  <last_update_submitted_qc>April 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>King Hussein Cancer Center</investigator_affiliation>
    <investigator_full_name>Mahmoud Al-Masri</investigator_full_name>
    <investigator_title>Chairman, Department of Surgery</investigator_title>
  </responsible_party>
  <keyword>seroma</keyword>
  <keyword>axillary</keyword>
  <keyword>dissection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Seroma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

